craft-sa-dev Home  

PMC:1584416 / 22251-23534 JSONTXT 5 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T3772 0-2 NN denotes Ne
T3771 0-9 sentence denotes Next we a
T3773 2-4 NNS denotes xt
T3774 4-5 : denotes
T3775 5-7 VBD denotes we
T3776 8-9 DT denotes a
T3778 9-11 NN denotes sk
T3777 9-19 sentence denotes sked wheth
T3779 11-12 VBZ denotes e
T3781 12-13 NN denotes d
T3782 14-16 IN denotes wh
T3783 16-17 NNS denotes e
T3780 17-18 VBP denotes t
T3784 18-19 IN denotes h
T3786 19-21 NN denotes er
T3785 19-23 sentence denotes er t
T3787 22-23 NN denotes t
T3789 23-24 DT denotes h
T3788 23-25 sentence denotes he
T3790 24-25 NN denotes e
T3791 25-26 sentence denotes
T3793 26-27 NN denotes X
T3792 26-29 sentence denotes Xpd
T3794 27-28 NN denotes p
T3795 28-29 NN denotes d
T3797 29-34 NN denotes †XPCS
T3796 29-48 sentence denotes †XPCS and Xpd†XP al
T3798 35-38 CC denotes and
T3799 39-42 NN denotes Xpd
T3800 42-45 NN denotes †XP
T3801 46-47 JJ denotes a
T3802 47-48 NN denotes l
T3804 48-49 NNS denotes l
T3803 48-66 sentence denotes leles, despite dec
T3805 49-50 VBP denotes e
T3806 50-53 NNS denotes les
T3807 53-55 , denotes ,
T3808 55-56 NN denotes d
T3809 56-58 NNS denotes es
T3810 58-59 NN denotes p
T3811 59-61 IN denotes it
T3812 61-62 NNS denotes e
T3813 63-64 VBN denotes d
T3814 64-65 NNS denotes e
T3815 65-66 NNS denotes c
T3817 66-68 JJ denotes re
T3816 66-74 sentence denotes reased m
T3818 68-69 NN denotes a
T3819 69-70 RBS denotes s
T3820 70-71 NNS denotes e
T3821 71-72 CC denotes d
T3822 73-74 NNS denotes m
T3826 74-77 NN denotes RNA
T3823 74-207 sentence denotes RNA levels, ameliorated TTD symptoms by increasing overall TFIIH levels in compound heterozygous XpdTTD/ †XPCS and XpdTTD/ †XP cells.
T3825 78-84 NNS denotes levels
T3827 84-86 , denotes ,
T3824 86-97 VBN denotes ameliorated
T3828 98-101 NN denotes TTD
T3829 102-110 NNS denotes symptoms
T3830 111-113 IN denotes by
T3831 114-124 VBG denotes increasing
T3833 125-132 JJ denotes overall
T3834 133-138 NN denotes TFIIH
T3832 139-145 NNS denotes levels
T3835 146-148 IN denotes in
T3836 149-157 NN denotes compound
T3838 158-170 JJ denotes heterozygous
T3839 171-177 NN denotes XpdTTD
T3841 177-178 HYPH denotes /
T3840 178-184 NN denotes  †XPCS
T3842 185-188 CC denotes and
T3843 189-195 NN denotes XpdTTD
T3845 195-196 HYPH denotes /
T3844 196-200 NN denotes  †XP
T3837 201-206 NNS denotes cells
T3846 206-207 . denotes .
T3847 207-429 sentence denotes Previously, using comparative immunohistochemistry, we and others have shown an up to 70% reduction of TFIIH levels in primary fibroblasts from patients with TTD compared with wt controls due to reduced stability [16,17].
T3848 208-218 RB denotes Previously
T3850 218-220 , denotes ,
T3851 220-225 VBG denotes using
T3852 226-237 JJ denotes comparative
T3853 238-258 NN denotes immunohistochemistry
T3854 258-260 , denotes ,
T3855 260-262 PRP denotes we
T3856 263-266 CC denotes and
T3857 267-273 NNS denotes others
T3858 274-278 VBP denotes have
T3849 279-284 VBN denotes shown
T3859 285-287 DT denotes an
T3861 288-290 IN denotes up
T3863 291-293 IN denotes to
T3862 294-296 CD denotes 70
T3864 296-297 NN denotes %
T3860 298-307 NN denotes reduction
T3865 308-310 IN denotes of
T3866 311-316 NN denotes TFIIH
T3867 317-323 NNS denotes levels
T3868 324-326 IN denotes in
T3869 327-334 JJ denotes primary
T3870 335-346 NNS denotes fibroblasts
T3871 347-351 IN denotes from
T3872 352-360 NNS denotes patients
T3873 361-365 IN denotes with
T3874 366-369 NN denotes TTD
T3875 370-378 VBN denotes compared
T3876 379-383 IN denotes with
T3877 384-386 NN denotes wt
T3878 387-395 NNS denotes controls
T3879 396-399 IN denotes due
T3880 400-402 IN denotes to
T3881 403-410 VBN denotes reduced
T3882 411-420 NN denotes stability
T3883 421-422 -LRB- denotes [
T3885 422-424 CD denotes 16
T3886 424-425 , denotes ,
T3884 425-427 CD denotes 17
T3887 427-428 -RRB- denotes ]
T3888 428-429 . denotes .
T3889 429-683 sentence denotes Despite overexpression of mRNA from the XpdTTD allele relative to the wt allele (Figure 1E), TFIIH protein levels were reduced by 50% in primary mouse XpdTTD/TTD fibroblasts (Figure 4E and 4F), thereby mimicking the situation in human patients with TTD.
T3890 430-437 IN denotes Despite
T3892 438-452 NN denotes overexpression
T3893 453-455 IN denotes of
T3894 456-460 NN denotes mRNA
T3895 461-465 IN denotes from
T3896 466-469 DT denotes the
T3898 470-476 NN denotes XpdTTD
T3897 477-483 NN denotes allele
T3899 484-492 JJ denotes relative
T3900 493-495 IN denotes to
T3901 496-499 DT denotes the
T3903 500-502 NN denotes wt
T3902 503-509 NN denotes allele
T3904 510-511 -LRB- denotes (
T3906 511-517 NN denotes Figure
T3905 518-520 NN denotes 1E
T3907 520-521 -RRB- denotes )
T3908 521-523 , denotes ,
T3909 523-528 NN denotes TFIIH
T3911 529-536 NN denotes protein
T3910 537-543 NNS denotes levels
T3912 544-548 VBD denotes were
T3891 549-556 VBN denotes reduced
T3913 557-559 IN denotes by
T3914 560-562 CD denotes 50
T3915 562-563 NN denotes %
T3916 564-566 IN denotes in
T3917 567-574 JJ denotes primary
T3919 575-580 NN denotes mouse
T3920 581-587 NN denotes XpdTTD
T3922 587-588 HYPH denotes /
T3921 588-591 NN denotes TTD
T3918 592-603 NNS denotes fibroblasts
T3923 604-605 -LRB- denotes (
T3925 605-611 NN denotes Figure
T3924 612-614 NN denotes 4E
T3926 615-618 CC denotes and
T3927 619-621 NN denotes 4F
T3928 621-622 -RRB- denotes )
T3929 622-624 , denotes ,
T3930 624-631 RB denotes thereby
T3931 632-641 VBG denotes mimicking
T3932 642-645 DT denotes the
T3933 646-655 NN denotes situation
T3934 656-658 IN denotes in
T3935 659-664 JJ denotes human
T3936 665-673 NNS denotes patients
T3937 674-678 IN denotes with
T3938 679-682 NN denotes TTD
T3939 682-683 . denotes .
T3940 683-812 sentence denotes In accordance with the gene dosage, a further reduction of up to 70% of the wt level was observed in hemizygous XpdTTD/KO cells.
T3941 684-686 IN denotes In
T3943 687-697 NN denotes accordance
T3944 698-702 IN denotes with
T3945 703-706 DT denotes the
T3947 707-711 NN denotes gene
T3946 712-718 NN denotes dosage
T3948 718-720 , denotes ,
T3949 720-721 DT denotes a
T3951 722-729 JJ denotes further
T3950 730-739 NN denotes reduction
T3952 740-742 IN denotes of
T3953 743-745 IN denotes up
T3955 746-748 IN denotes to
T3954 749-751 CD denotes 70
T3956 751-752 NN denotes %
T3957 753-755 IN denotes of
T3958 756-759 DT denotes the
T3960 760-762 NN denotes wt
T3959 763-768 NN denotes level
T3961 769-772 VBD denotes was
T3942 773-781 VBN denotes observed
T3962 782-784 IN denotes in
T3963 785-795 JJ denotes hemizygous
T3965 796-802 NN denotes XpdTTD
T3967 802-803 HYPH denotes /
T3966 803-805 NN denotes KO
T3964 806-811 NNS denotes cells
T3968 811-812 . denotes .
T3969 812-1006 sentence denotes Consistent with low mRNA expression levels, neither the Xpd†XPCS nor the Xpd†XP allele was able to restore TFIIH abundance to wt levels in XpdTTD compound heterozygote cells (Figure 4E and 4F).
T3970 813-823 JJ denotes Consistent
T3972 824-828 IN denotes with
T3973 829-832 JJ denotes low
T3975 833-837 NN denotes mRNA
T3976 838-848 NN denotes expression
T3974 849-855 NNS denotes levels
T3977 855-857 , denotes ,
T3978 857-864 CC denotes neither
T3980 865-868 DT denotes the
T3981 869-877 NN denotes Xpd†XPCS
T3982 878-881 CC denotes nor
T3983 882-885 DT denotes the
T3984 886-892 NN denotes Xpd†XP
T3979 893-899 NN denotes allele
T3971 900-903 VBD denotes was
T3985 904-908 JJ denotes able
T3986 909-911 TO denotes to
T3987 912-919 VB denotes restore
T3988 920-925 NN denotes TFIIH
T3989 926-935 NN denotes abundance
T3990 936-938 IN denotes to
T3991 939-941 NN denotes wt
T3992 942-948 NNS denotes levels
T3993 949-951 IN denotes in
T3994 952-958 NN denotes XpdTTD
T3996 959-967 NN denotes compound
T3997 968-980 NN denotes heterozygote
T3995 981-986 NNS denotes cells
T3998 987-988 -LRB- denotes (
T4000 988-994 NN denotes Figure
T3999 995-997 NN denotes 4E
T4001 998-1001 CC denotes and
T4002 1002-1004 NN denotes 4F
T4003 1004-1005 -RRB- denotes )
T4004 1005-1006 . denotes .
T4005 1006-1283 sentence denotes Thus, the improved UV survival observed in compound heterozygote cells (Figure 4A) and likely the rescue of TTD progeroid symptoms (Figure 3) were not due to normalisation of TFIIH levels, suggesting a qualitative rather than a quantitative effect on these phenotypes in vivo.
T4006 1007-1011 RB denotes Thus
T4008 1011-1013 , denotes ,
T4009 1013-1016 DT denotes the
T4011 1017-1025 VBN denotes improved
T4012 1026-1028 NN denotes UV
T4010 1029-1037 NN denotes survival
T4013 1038-1046 VBN denotes observed
T4014 1047-1049 IN denotes in
T4015 1050-1058 NN denotes compound
T4017 1059-1071 NN denotes heterozygote
T4016 1072-1077 NNS denotes cells
T4018 1078-1079 -LRB- denotes (
T4020 1079-1085 NN denotes Figure
T4019 1086-1088 NN denotes 4A
T4021 1088-1089 -RRB- denotes )
T4022 1090-1093 CC denotes and
T4023 1094-1100 RB denotes likely
T4025 1101-1104 DT denotes the
T4024 1105-1111 NN denotes rescue
T4026 1112-1114 IN denotes of
T4027 1115-1118 NN denotes TTD
T4029 1119-1128 NN denotes progeroid
T4028 1129-1137 NNS denotes symptoms
T4030 1138-1139 -LRB- denotes (
T4031 1139-1145 NN denotes Figure
T4032 1146-1147 CD denotes 3
T4033 1147-1148 -RRB- denotes )
T4007 1149-1153 VBD denotes were
T4034 1154-1157 RB denotes not
T4035 1158-1161 IN denotes due
T4036 1162-1164 IN denotes to
T4037 1165-1178 NN denotes normalisation
T4038 1179-1181 IN denotes of
T4039 1182-1187 NN denotes TFIIH
T4040 1188-1194 NNS denotes levels
T4041 1194-1196 , denotes ,
T4042 1196-1206 VBG denotes suggesting
T4043 1207-1208 DT denotes a
T4044 1209-1220 JJ denotes qualitative
T4046 1221-1227 RB denotes rather
T4047 1228-1232 IN denotes than
T4048 1233-1234 DT denotes a
T4049 1235-1247 JJ denotes quantitative
T4045 1248-1254 NN denotes effect
T4050 1255-1257 IN denotes on
T4051 1258-1263 DT denotes these
T4052 1264-1274 NNS denotes phenotypes
T4053 1275-1277 FW denotes in
T4054 1278-1282 FW denotes vivo
T4055 1282-1283 . denotes .
R2518 T3778 T3779 nsubj sk,e
R2519 T3779 T3780 ccomp e,t
R2520 T3781 T3779 dobj d,e
R2521 T3782 T3781 prep wh,d
R2522 T3783 T3780 nsubj e,t
R2523 T3789 T3790 det h,e
R2524 T3798 T3797 cc and,†XPCS
R2525 T3799 T3800 compound Xpd,†XP
R2526 T3800 T3797 conj †XP,†XPCS
R2527 T3801 T3802 amod a,l
R2528 T3804 T3805 nsubj l,e
R2529 T3806 T3805 dobj les,e
R2530 T3812 T3811 pobj e,it
R2531 T3817 T3818 amod re,a
R2532 T3821 T3820 cc d,e
R2533 T3822 T3820 conj m,e
R2534 T3826 T3825 compound RNA,levels
R2535 T3827 T3824 punct ", ",ameliorated
R2536 T3828 T3829 compound TTD,symptoms
R2537 T3829 T3824 dobj symptoms,ameliorated
R2538 T3830 T3824 prep by,ameliorated
R2539 T3831 T3832 amod increasing,levels
R2540 T3832 T3830 pobj levels,by
R2541 T3833 T3832 amod overall,levels
R2542 T3834 T3832 compound TFIIH,levels
R2543 T3835 T3824 prep in,ameliorated
R2544 T3836 T3837 nmod compound,cells
R2545 T3837 T3835 pobj cells,in
R2546 T3838 T3837 amod heterozygous,cells
R2547 T3839 T3840 nmod XpdTTD, †XPCS
R2548 T3840 T3837 nmod  †XPCS,cells
R2549 T3841 T3840 punct /, †XPCS
R2550 T3842 T3840 cc and, †XPCS
R2551 T3843 T3844 compound XpdTTD, †XP
R2552 T3844 T3840 conj  †XP, †XPCS
R2553 T3845 T3844 punct /, †XP
R2554 T3848 T3849 advmod Previously,shown
R2555 T3850 T3849 punct ", ",shown
R2556 T3851 T3849 advcl using,shown
R2557 T3852 T3853 amod comparative,immunohistochemistry
R2558 T3853 T3851 dobj immunohistochemistry,using
R2559 T3854 T3849 punct ", ",shown
R2560 T3855 T3849 nsubj we,shown
R2561 T3856 T3855 cc and,we
R2562 T3857 T3855 conj others,we
R2563 T3858 T3849 aux have,shown
R2564 T3859 T3860 det an,reduction
R2565 T3860 T3849 dobj reduction,shown
R2566 T3861 T3862 quantmod up,70
R2567 T3862 T3864 nummod 70,%
R2568 T3863 T3862 quantmod to,70
R2569 T3864 T3860 compound %,reduction
R2570 T3865 T3860 prep of,reduction
R2571 T3866 T3867 compound TFIIH,levels
R2572 T3867 T3865 pobj levels,of
R2573 T3868 T3867 prep in,levels
R2574 T3869 T3870 amod primary,fibroblasts
R2575 T3870 T3868 pobj fibroblasts,in
R2576 T3871 T3870 prep from,fibroblasts
R2577 T3872 T3871 pobj patients,from
R2578 T3873 T3872 prep with,patients
R2579 T3874 T3873 pobj TTD,with
R2580 T3875 T3860 prep compared,reduction
R2581 T3876 T3875 prep with,compared
R2582 T3877 T3878 compound wt,controls
R2583 T3878 T3876 pobj controls,with
R2584 T3879 T3860 prep due,reduction
R2585 T3880 T3879 pcomp to,due
R2586 T3881 T3882 amod reduced,stability
R2587 T3882 T3879 pobj stability,due
R2588 T3883 T3884 punct [,17
R2589 T3884 T3849 parataxis 17,shown
R2590 T3885 T3884 nummod 16,17
R2591 T3886 T3884 punct ",",17
R2592 T3887 T3884 punct ],17
R2593 T3888 T3849 punct .,shown
R2594 T3890 T3891 prep Despite,reduced
R2595 T3892 T3890 pobj overexpression,Despite
R2596 T3893 T3892 prep of,overexpression
R2597 T3894 T3893 pobj mRNA,of
R2598 T3895 T3894 prep from,mRNA
R2599 T3896 T3897 det the,allele
R2600 T3897 T3895 pobj allele,from
R2601 T3898 T3897 compound XpdTTD,allele
R2602 T3899 T3892 amod relative,overexpression
R2603 T3900 T3899 prep to,relative
R2604 T3901 T3902 det the,allele
R2605 T3902 T3900 pobj allele,to
R2606 T3903 T3902 compound wt,allele
R2607 T3904 T3905 punct (,1E
R2608 T3905 T3892 parataxis 1E,overexpression
R2609 T3906 T3905 compound Figure,1E
R2610 T3907 T3905 punct ),1E
R2611 T3908 T3891 punct ", ",reduced
R2612 T3909 T3910 compound TFIIH,levels
R2613 T3910 T3891 nsubjpass levels,reduced
R2614 T3911 T3910 compound protein,levels
R2615 T3912 T3891 auxpass were,reduced
R2616 T3913 T3891 prep by,reduced
R2617 T3914 T3915 nummod 50,%
R2618 T3915 T3913 pobj %,by
R2619 T3916 T3891 prep in,reduced
R2620 T3917 T3918 amod primary,fibroblasts
R2621 T3918 T3916 pobj fibroblasts,in
R2622 T3919 T3918 compound mouse,fibroblasts
R2623 T3920 T3921 compound XpdTTD,TTD
R2624 T3921 T3918 compound TTD,fibroblasts
R2625 T3922 T3921 punct /,TTD
R2626 T3923 T3924 punct (,4E
R2627 T3924 T3891 parataxis 4E,reduced
R2628 T3925 T3924 compound Figure,4E
R2629 T3926 T3924 cc and,4E
R2630 T3927 T3924 conj 4F,4E
R2631 T3928 T3924 punct ),4E
R2632 T3929 T3891 punct ", ",reduced
R2633 T3930 T3931 advmod thereby,mimicking
R2634 T3931 T3891 advcl mimicking,reduced
R2635 T3932 T3933 det the,situation
R2636 T3933 T3931 dobj situation,mimicking
R2637 T3934 T3931 prep in,mimicking
R2638 T3935 T3936 amod human,patients
R2639 T3936 T3934 pobj patients,in
R2640 T3937 T3936 prep with,patients
R2641 T3938 T3937 pobj TTD,with
R2642 T3939 T3891 punct .,reduced
R2643 T3941 T3942 prep In,observed
R2644 T3943 T3941 pobj accordance,In
R2645 T3944 T3943 prep with,accordance
R2646 T3945 T3946 det the,dosage
R2647 T3946 T3944 pobj dosage,with
R2648 T3947 T3946 compound gene,dosage
R2649 T3948 T3942 punct ", ",observed
R2650 T3949 T3950 det a,reduction
R2651 T3950 T3942 nsubjpass reduction,observed
R2652 T3951 T3950 amod further,reduction
R2653 T3952 T3950 prep of,reduction
R2654 T3953 T3954 quantmod up,70
R2655 T3954 T3956 nummod 70,%
R2656 T3955 T3954 quantmod to,70
R2657 T3956 T3952 pobj %,of
R2658 T3957 T3956 prep of,%
R2659 T3958 T3959 det the,level
R2660 T3959 T3957 pobj level,of
R2661 T3960 T3959 compound wt,level
R2662 T3961 T3942 auxpass was,observed
R2663 T3962 T3942 prep in,observed
R2664 T3963 T3964 amod hemizygous,cells
R2665 T3964 T3962 pobj cells,in
R2666 T3965 T3966 compound XpdTTD,KO
R2667 T3966 T3964 compound KO,cells
R2668 T3967 T3966 punct /,KO
R2669 T3968 T3942 punct .,observed
R2670 T3970 T3971 advcl Consistent,was
R2671 T3972 T3970 prep with,Consistent
R2672 T3973 T3974 amod low,levels
R2673 T3974 T3972 pobj levels,with
R2674 T3975 T3976 compound mRNA,expression
R2675 T3976 T3974 compound expression,levels
R2676 T3977 T3971 punct ", ",was
R2677 T3978 T3979 preconj neither,allele
R2678 T3979 T3971 nsubj allele,was
R2679 T3980 T3981 det the,Xpd†XPCS
R2680 T3981 T3979 nmod Xpd†XPCS,allele
R2681 T3982 T3981 cc nor,Xpd†XPCS
R2682 T3983 T3984 det the,Xpd†XP
R2683 T3984 T3981 conj Xpd†XP,Xpd†XPCS
R2684 T3985 T3971 acomp able,was
R2685 T3986 T3987 aux to,restore
R2686 T3987 T3985 xcomp restore,able
R2687 T3988 T3989 compound TFIIH,abundance
R2688 T3989 T3987 dobj abundance,restore
R2689 T3990 T3987 prep to,restore
R2690 T3991 T3992 compound wt,levels
R2691 T3992 T3990 pobj levels,to
R2692 T3993 T3987 prep in,restore
R2693 T3994 T3995 compound XpdTTD,cells
R2694 T3995 T3993 pobj cells,in
R2695 T3996 T3995 compound compound,cells
R2696 T3997 T3995 compound heterozygote,cells
R2697 T3998 T3999 punct (,4E
R2698 T3999 T3971 parataxis 4E,was
R2699 T4000 T3999 compound Figure,4E
R2700 T4001 T3999 cc and,4E
R2701 T4002 T3999 conj 4F,4E
R2702 T4003 T3999 punct ),4E
R2703 T4004 T3971 punct .,was
R2704 T4006 T4007 advmod Thus,were
R2705 T4008 T4007 punct ", ",were
R2706 T4009 T4010 det the,survival
R2707 T4010 T4007 nsubj survival,were
R2708 T4011 T4010 amod improved,survival
R2709 T4012 T4010 compound UV,survival
R2710 T4013 T4010 acl observed,survival
R2711 T4014 T4013 prep in,observed
R2712 T4015 T4016 compound compound,cells
R2713 T4016 T4014 pobj cells,in
R2714 T4017 T4016 compound heterozygote,cells
R2715 T4018 T4019 punct (,4A
R2716 T4019 T4013 parataxis 4A,observed
R2717 T4020 T4019 compound Figure,4A
R2718 T4021 T4019 punct ),4A
R2719 T4022 T4013 cc and,observed
R2720 T4023 T4024 advmod likely,rescue
R2721 T4024 T4013 conj rescue,observed
R2722 T4025 T4024 det the,rescue
R2723 T4026 T4024 prep of,rescue
R2724 T4027 T4028 compound TTD,symptoms
R2725 T4028 T4026 pobj symptoms,of
R2726 T4029 T4028 compound progeroid,symptoms
R2727 T4030 T4031 punct (,Figure
R2728 T4031 T4024 parataxis Figure,rescue
R2729 T4032 T4031 nummod 3,Figure
R2730 T4033 T4031 punct ),Figure
R2731 T4034 T4007 neg not,were
R2732 T4035 T4007 prep due,were
R2733 T4036 T4035 pcomp to,due
R2734 T4037 T4035 pobj normalisation,due
R2735 T4038 T4037 prep of,normalisation
R2736 T4039 T4040 compound TFIIH,levels
R2737 T4040 T4038 pobj levels,of
R2738 T4041 T4007 punct ", ",were
R2739 T4042 T4007 advcl suggesting,were
R2740 T4043 T4044 advmod a,qualitative
R2741 T4044 T4045 amod qualitative,effect
R2742 T4045 T4042 dobj effect,suggesting
R2743 T4046 T4047 advmod rather,than
R2744 T4047 T4044 cc than,qualitative
R2745 T4048 T4049 advmod a,quantitative
R2746 T4049 T4044 conj quantitative,qualitative
R2747 T4050 T4045 prep on,effect
R2748 T4051 T4052 det these,phenotypes
R2749 T4052 T4050 pobj phenotypes,on
R2750 T4053 T4054 advmod in,vivo
R2751 T4054 T4045 advmod vivo,effect
R2752 T4055 T4007 punct .,were